Loading Ticker...
You Are Here: Home » Pharma

USFDA approval for Lupin’s Suprax Oral Suspension

Drug Firm Lupin Ltd announced today that its subsidiary Lupin Pharmaceuticals has received approval from the United States Food and Drugs Administration (US FDA) for its Oral suspension – Suprax in the strength of 500mg/5mL. The company expects to start shipping the product in near future.

Lupin Pharma Logo

Lupin Pharma Logo

Presently Suprax is available as 100 mg/5ml and 200 mg/5ml suspensions, 400 mg tablets as well as chewable tablets 100 & 200 mg.

The company said that this approval from the US health regulator will expand the company’s range of Suprax dosage forms available to treat approved indications in appropriate patients.

Vinita Gupta, Group president, Lupin & CEO,Lupin Pharmaceuticals Inc. commented on the approval by saying that The new dosage form will add to their growing Suprax franchise and will also provide health care providers and patients a new formulation to treat infections.

Lupin is the 5th largest and fastest growing generics company in the US and the 3rd largest Indian pharmaceutical company in terms of sales.


Share this post

Subscribe to our updates via e-mail or get our  RSS Feed
Enter your email address:

Other Related Stories: